Compare Kimberly Clark Corp (KMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Kimberly Clark Corp is far larger — about 3.2× State Street SPDR S&P Biotech ETF's market cap, and Kimberly Clark Corp pays a 5.24% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KMB | XBI | |
|---|---|---|
Market Cap | $32.51B | $10.11B |
Volume | 6,139,913 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $121.44 | $169.55 |
52-Week Low | $93.05 | $104.99 |
Typical Hold Time | 93 Days | 38 Days |
Enterprise Value | $38.07B | — |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though Q2 2026 earnings missed expectations. Recent news highlights executive transitions and the pending Kenvue acquisition, while dividend sustainability questions emerge amid cash flow pressures. Analyst consensus remains cautious with 61% hold ratings despite a $117.25 price target suggesting 20% upside.
KMB presents a value opportunity with attractive dividend yield near 5%, but faces integration risks from the Kenvue deal and cash flow challenges. The stock's current discount to analyst targets offers potential upside if execution improves, though investors should monitor dividend coverage and acquisition integration closely given the bearish technical trend and mixed earnings performance.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
